背景:IBD是一系列病理,其特征是免疫激活失调,导致对肠道的不受控制的反应,从而导致慢性肠道炎症和组织损伤。由于其复杂性,导致疾病发作和进展的分子机制仍然难以捉摸,因此需要紧张的研究努力。在这种情况下,开发复制IBD病因病理学的模型并允许测试新的潜在治疗方法至关重要.
方法:将来自C57BL/6或BALB/c小鼠的结肠在GEVS中培养,暴露于DNBS1.5或2.5mg/mL5小时,在存在或不存在两种益生菌制剂的情况下(P1=短双歧杆菌BR03(DSM16604)和B632(DSM24706);P2=鼠李糖乳杆菌LR04(DSM16605),植物乳杆菌LP14(DSM33401)和副干酪乳杆菌LPC09),并对IBD的主要标志进行了评价。
结果:基因表达分析揭示了以下DNBS诱导的作用:(i)紧密连接组织受损,负责组织渗透性失调;(ii)内质网应激的诱导,和(iii)C57BL/6小鼠结肠中的组织炎症。此外,伴随DNBS诱导的细胞凋亡和铁凋亡途径在BALB/c和C57BL/6小鼠的结肠中均明显。最后,益生菌的共同给药完全防止了DNBS的有害作用。
结论:总体而言,我们提供的结果表明,GEVS是一致的,可靠,以及用于模拟DNBS诱导的IBD的经济高效系统,有助于在分子水平上研究人类疾病的发病和进展,同时也减少了动物的痛苦。此外,我们已经证实了益生菌在促进IBD缓解方面的有益作用。
BACKGROUND: IBD is a spectrum of pathologies characterized by dysregulated immune activation leading to uncontrolled response against the intestine, thus resulting in chronic gut inflammation and tissue damage. Due to its complexity, the molecular mechanisms responsible for disease onset and progression are still elusive, thus requiring intense research effort. In this context, the development of models replicating the etiopathology of IBD and allowing the testing of new potential therapies is critical.
METHODS: Colon from C57BL/6 or BALB/c mice was cultivated in a Gut-Ex-Vivo System (GEVS), exposed for 5 h to
DNBS 1.5 or 2.5 mg/mL, in presence or absence of two probiotic formulations (P1 = Bifidobacterium breve BR03 (DSM16604) and B632 (DSM24706); P2 = Lacticaseibacillus rhamnosus LR04 (DSM16605), Lactiplantibacillus plantarum LP14 (DSM33401) and Lacticaseibacillus paracasei LPC09), and the main hallmarks of IBD were evaluated.
RESULTS: Gene expression analysis revealed the following
DNBS-induced effects: (i) compromised tight junction organization, responsible for tissue permeability dysregulation; (ii) induction of ER stress, and (iii) tissue inflammation in colon of C57BL/6 mice. Moreover, the concomitant
DNBS-induced apoptosis and ferroptosis pathways were evident in colon from both BALB/c and C57BL/6 mice. Finally, the co-administration of probiotics completely prevented the detrimental effects of
DNBS.
CONCLUSIONS: Overall, we have provided results demonstrating that GEVS is a consistent, reliable, and cost-effective system for modeling
DNBS-induced IBD, useful for studying the onset and progression of human disease at the molecular level, while also reducing animal suffering. Moreover, we have confirmed the beneficial effect of probiotics administration in promoting the remission of IBD.